Famotidine and Antacids for Treatment of Dyspepsia

Recruiting now · Phase 4

Conditions studied: Dyspepsia, GERD, Acid Reflux

In brief

The aim of this study is to compare intravenous famotidine, an H2 receptor antagonist, and Maalox/ Mylanta, an oral antacid, in treatment of dyspepsia in the emergency department. The goal of this study is to reduce patients' pain based on the verbal numerical pain scale. The anticipated outcome is for pain levels in both groups to decrease. It is expected that antacids will improve symptoms more quickly and to a greater degree within an hour of taking medication based on the results of similar studies.

Key facts

Study ID

NCT06241183

Run by

Stony Brook University

People needed

80

Starts

2023-11-09

Expected to finish

2027-12-31

Last updated by the study team

2026-06-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject Age ≥ 18 years of age
• Patient diagnosed with dyspepsia
• Present at the ED with upper abdominal pain score of at least 3

You may not qualify if…

• Hypersensitivity to an ingredient in Maalox/ Mylanta or Famotidine
• Moderate to Severe Renal Insufficiency (precaution)
• Kidney Failure
• Pregnant or Nursing
• Verbal pain score less than 3
• Inability to tolerate oral medications
• Bowel Obstruction
• Proton pump inhibitor within 2 hours of study treatment

Where it is running

• Stony Brook University Hospital — Stony Brook, New York, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.